wave graphic mobile

Cell Therapy Technologies

Building Scalable, Reliable Platforms for Advanced Therapies

Cell therapy developers face persistent challenges, including long vein-to-vein times, high and variable costs of goods, deviations and non-conforming events, contamination, inconsistent yields, lengthy project timelines from contract signature to ready-to-use GMP drug product, and complex regulatory requirements.

Minaris Advanced Therapies has created technology platforms that directly address these barriers. With automated closed systems, optimized expansion protocols and scalable bioreactor solutions, we help innovators deliver consistent therapies that are cost-efficient and GMP-ready.

Connect With Our Experts

Where We Make the Difference

Reducing manufacturing time and cost in autologous CAR-T and TIL programs

Closed and automated state-of-the-art cell processing equipment for robustness and efficiency

Modular process workflow design for quick assembly and shortening of the project timeline

Highly experienced process development and manufacturing team to ensure project success

Improving consistency and scalability in allogeneic CAR-T, TIL, Treg, NK, MSC and HSC platforms

CAR-T Manufacturing Platforms for Faster Timelines

Automated closed systems that shorten vein-to-vein time and improve consistency.

Traditional autologous CAR-T production can take up to two weeks, raising treatment risk as patients wait. Manual operations increase the risk of contamination and associated costs. Minaris has developed a closed automated workflow that can shorten the autologous CAR-T process to 6 days, which yields sufficient CAR+ cells for most CAR-T therapy needs. With more than 150 GMP CAR-T batches delivered, we provide a proven path from Phase I through commercial readiness.

Our Cell Therapy Platforms at a Glance

  • CAR-T
    Closed systems for faster turnaround and consistent release

  • TIL
    Optimized expansion that reduces variability and saves time

  • MSC
    3D bioreactors for scalable, cost-efficient yield

  • HSC
    Closed automated workflow to ensure high purity and robustness

Why Minaris for Cell Therapy Innovation

With more than 7,500 GMP batches manufactured, Minaris combines global scale with proprietary innovation. Our platforms shorten vein-to-vein time, reduce the cost of goods and improve consistency across autologous and allogeneic therapies. Integrated with all Cell Therapy Services, Cell Therapy Process and Analytical Development, Cell Therapy GMP Manufacturing and Minaris Advanced Testing, we provide a seamless pathway from early research to global commercialization.

Speak With Our Cell Therapy Experts

Explore All
Minaris Services

Contact Us

Minaris Advanced Therapies is dedicated to helping innovators in cell and gene therapy succeed. Whether you are in early-stage development or preparing for commercial launch, our end-to-end expertise, global reach and commitment to quality make us the ideal partner for cell and gene therapy manufacturing and GMP biosafety and analytical testing of all biologics.

Get in Touch